GLP-1 drugs and insulin resistance: what the caption gets right and wrong

What's this video probably claiming?

Based on the caption and hashtag context, @sonyarnmetabolic is making a two-part argument. First, that GLP-1 receptor agonists work through appetite suppression, delayed gastric emptying, and improved glucose handling. Second, and more provocatively, that if underlying insulin resistance persists, weight loss from GLP-1 therapy is somehow undermined because the body remains metabolically "wired" to store fat and drive hunger. The creator appears to be positioning insulin resistance as a root cause that GLP-1 drugs treat around rather than through. This framing is popular in metabolic health content circles and is not entirely wrong, but it compresses a genuinely complicated physiological story into a narrative that conveniently overstates the limitations of GLP-1 therapy. That deserves some scrutiny before 26,600 viewers walk away thinking their medication is missing the point.

What does the science actually show?

GLP-1 receptor agonists do reduce appetite and slow gastric emptying, that part is textbook. But the claim that these drugs leave insulin resistance untouched is where the caption starts to wobble. Semaglutide trials, including the STEP 1 trial (Wilding et al., 2021, NEJM), showed 14.9% mean body weight reduction over 68 weeks at 2.4mg weekly dosing, and metabolic improvements that went well beyond appetite suppression. Tirzepatide data from SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed up to 22.5% weight loss at 15mg weekly, with significant reductions in HOMA-IR, a standard proxy for insulin resistance. These drugs actually improve insulin sensitivity, partly through weight loss itself and partly through direct effects on pancreatic beta-cell function and hepatic glucose production. The idea that insulin resistance sits completely outside their mechanism is not well supported by the trial data.

Where does the social media noise diverge from clinical reality?

The framing that GLP-1 drugs are a symptomatic band-aid while insulin resistance hums along underneath is a recurring social media narrative, and it tends to serve a secondary agenda: promoting additional interventions like specific diets, supplements, or coaching programs. Clinically, the picture is more nuanced. Insulin resistance is not a binary switch. It exists on a spectrum and responds to caloric deficit, weight loss, and exercise regardless of mechanism. A 2023 meta-analysis by Gorgojo-Martinez et al. in Diabetes, Obesity and Metabolism found that GLP-1 receptor agonist therapy significantly reduced fasting insulin and improved insulin sensitivity indexes across multiple trials. Framing GLP-1 therapy as ineffective against insulin resistance because the drug "doesn't fix the root cause" misrepresents what these medications actually do at the metabolic level. It also risks nudging people toward unproven adjunct therapies or away from medications that have strong mortality and cardiovascular outcome data behind them.

What should you actually know?

GLP-1 receptor agonists genuinely do improve insulin sensitivity, they do not just paper over it. That said, the creator is not entirely off base on one point: weight regain after stopping GLP-1 therapy is real and well-documented. The STEP 4 withdrawal trial (Rubino et al., 2021, JAMA) showed participants regained roughly two-thirds of lost weight within a year of stopping semaglutide. Whether that reflects persistent insulin resistance, restored appetite signaling, or the chronic nature of obesity as a disease is still being studied. The honest answer is that insulin resistance and obesity are bidirectional and intertwined, and no single drug or lifestyle change resolves all of it permanently for most people. Patients on GLP-1 therapy should have regular metabolic monitoring, not because the drugs are failing, but because obesity is a long-term condition that requires long-term management from a licensed provider.